Eton Pharmaceuticals, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Unaudited financial statements; dollar amounts below are in millions except per-share data.
Business context and results
Eton is a specialty pharmaceutical company focused on hospital injectables and pediatric rare-disease products. Its commercial portfolio included Biorphen and Alkindi Sprinkle; it also receives royalties on EM-100, launched by Bausch Health in January 2021. In February 2021, Eton sold rights to three pediatric neurology products to Azurity.
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Total revenue | $11.897 | $0.099 |
| Licensing revenue | $11.500 | $0 |
| Product sales and royalties | $0.397 | $0.099 |
| Gross profit (loss) | $10.307 | $(0.003) |
| Operating expenses | $4.944 | $8.878 |
| Operating income (loss) | $5.363 | $(8.881) |
| Net income (loss) | $5.116 | $(9.049) |
| Diluted EPS | $0.19 | $(0.50) |
| Operating cash flow | $3.715 | $(7.217) |
Gross margin was approximately 86.6%, driven principally by licensing revenue rather than recurring product sales. The filing identifies $0.254 of product sales and $0.143 of royalty revenue in Q1 2021. Licensing revenue increased from zero; product sales and royalties rose from $0.099.
Financial position and liquidity
- Cash and cash equivalents were $25.113 at March 31, 2021, up from $21.295 at December 31, 2020. Total assets were $31.186 and stockholders’ equity was $21.555.
- Current assets were $30.274 versus current liabilities of $3.199. Cash exceeded total recorded debt by approximately $18.0, using balance-sheet carrying amounts.
- SWK debt had $7.000 of gross principal and $6.568 of net carrying debt, including current and long-term portions. PPP and EIDL balances totaled about $0.511. SWK principal repayments begin in 2022, with the remaining balance due in November 2024.
- Cash increased $3.818 during the quarter. Operating activities provided $3.715; financing provided $0.103, primarily from employee stock-option exercises. Investing activities used no cash.
Material changes, outlook, and risks
- Net income and positive operating cash flow contrast with the prior-year net loss and operating cash outflow. The comparison reflects Q1 2020 Alkindi licensing costs, including $4.764 expensed in R&D, and Q1 2021 licensing milestone revenue.
- R&D expense fell to $0.886 from $6.268, reflecting lower development activity and the prior-year Alkindi expense. G&A increased to $4.058 from $2.610, mainly from compensation and Alkindi marketing and distribution costs.
- Management expects growth from market penetration of approved products and additional licensing and product revenue. It believes cash on hand will fund operating and capital needs for at least 12 months from filing, subject to sales and spending assumptions. No numerical full-year guidance was provided.
- Eton discontinued its Lake Zurich laboratory operation and classified $0.551 of equipment as held for sale, expecting a sale in May 2021 at a price above book value.
- SWK debt requires a minimum $3.0 cash balance and includes covenants limiting additional debt. The company said it was negotiating EBITDA and revenue covenant targets. PPP loan forgiveness was applied for but remained subject to SBA determination.
- Management cautioned that slower product growth, development or regulatory delays, or inability to obtain financing could require spending reductions or discontinuation of operations. Additional equity financing could dilute shareholders. The company reported no known pending or threatened litigation expected to have a material impact.
Key investor verification points
- Reconcile reported Q1 licensing revenue of $11.5 with the filing’s described Azurity proceeds of $9.5 and Bausch milestone of $1.5; those described amounts total $11.0, and the supplied filing text does not clearly explain the difference.
- Assess how much future revenue and cash generation can come from recurring product sales and royalties versus one-time licensing or milestone receipts.
- Track product launches, FDA decisions and milestone conditions for Azurity’s acquired products and Eton’s remaining pipeline.
- Monitor SWK covenant negotiations, debt service requirements, the minimum-cash covenant, and the SBA’s PPP forgiveness decision.
- Verify the laboratory equipment sale and the assumptions supporting management’s 12-month liquidity assessment.